FP6Индивидуална стипендия2004–2006

GLYCOMIGS · Sugar Mimetics: Multicomponent Inhibitors of Glycosyltransferases

6РП — Действия „Мария Кюри“

Период
2004-10-01 → 2006-09-30
Финансиране от ЕС
158 479 €
Участници
1
Схема
EIF

Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.

Накратко на български

Гликозилтрансферазните ензими се изследват чрез създаване на молекули, имитиращи захари, като пример са тези при микобактериите. Разработването на такива инхибитори помага за по-доброто разбиране на тези протеини и създаването на потенциални средства за лечение на туберкулоза.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Цел на проекта

The Inhibition of Glycosyltransferases as a Potential Therapeutic Target: It has been estimated that 2-3% of mammalian genomes are associated with the production of carbohydrate-processing proteins and enzymes. Of these by far the most widespread class of such proteins are glycosyltransferases (GlyTs). This remarkable but poorly understood class of enzymes are ubiquitous in nature and play a wide range of fundamental biological roles in events as diverse as fertilization, cancer, immunology, cell signalling and protein folding. Importantly, certain types that perform highly specific functions associated with disease states have been identified and offer themselves as potential targets for inhibition. Yet, to date few potent and specific inhibitors of any of the many thousand of potential enzyme targets have been identified. None are in development as drugs. We aim to develop and apply recent chemical discoveries in our laboratory for the construction of sugar mimetics to the creation of a new generation of mu lticomponent inhibitors of GlyTs. By using such a component assembly approach, we will design and optimize mimetic modules that will fit key binding pockets of these enzymes. In this way we will not only develop an improved understanding of this class of e nzymes but will also use this understanding to create potent inhibitors. As directly relevant GlyTs of high potential therapeutic utility, we have chosen to target Mycobacterial GlyTs as model systems in which to explore this novel but general modular meth odology that we believe will allow ready adaptation to other, important GlyT targets, such as e.g., fucosyltransferases. If successful this programme would therefore not only create leads of potential utility in the treatment of tuberculosis but methodolo gy applicable to other diseases associated with GlyTs e.g. mycocardial infarction and cancer metastasis.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз